


CLAIMS

1. A solid form of compound 1,



1

or a pharmaceutically acceptable salt thereof.

2. The solid form of claim 1, of crystalline form A2, wherein form A2 is characterized by two or more 2 θ XRPD peaks at 4.7, 17.5, and 20.6 degrees.
3. The solid form of claim 2, wherein form A2 is characterized by four or more 2 θ XRPD peaks at 4.7, 9.4, 15.0, 17.5, 17.9, 19.0, 19.7, 20.6 and 23.4 degrees.
4. The solid form of claim 1, of crystalline form NF4, wherein form NF4 is characterized by two or more 2 θ XRPD peaks at 4.7, 16.8, and 20.8 degrees.
5. The solid form of claim 4, wherein form NF4 is characterized by four or more 2 θ XRPD peaks at 4.7, 9.5, 16.8, 17.4, 17.7, 19.8, 20.4, and 20.8 degrees.
6. The solid form of claim 1, of crystalline form NF5, wherein form NF4 is characterized by two or more 2 θ XRPD peaks at 4.7, 9.4, and 20.1 degrees.
7. The solid form of claim 6, wherein form NF5 is characterized by four or more 2 θ XRPD peaks at 4.7, 9.4, 13.3, 14.2, 17.0, 17.3, 17.5, 20.1, and 21.1 degrees.

8. The solid form of claim 1, of crystalline form NF6, wherein form NF4 is characterized by two or more 2 θ XRPD peaks at 4.79, 17.39, and 20.01 degrees.
9. The solid form of claim 8, wherein form NF6 is characterized by four or more 2 θ XRPD peaks at 4.79, 9.56, 15.16, 17.39, 20.01, 20.57, 22.10, 23.38, and 23.73 degrees.
10. The solid form of claim 1, selected from solid form Malonate-NF1 of a malonate salt of compound 1, solid form Succinate-NF1 of a succinate salt of compound 1, solid form Oxalate-NF1 of an oxalate salt of compound 1, solid form Fumarate-NF1 of a fumarate salt of compound 1, solid form Maleate-NF1 of a maleate salt of compound 1, solid form L-Malate-NF1 of a L-malate salt of compound 1, and solid form Citrate-NF1 of a citrate salt of compound 1.
11. The solid form of claim 1, selected from solid form Malonate-NF1 of a malonate salt of compound 1, solid form Succinate-NF1 of a succinate salt of compound 1, solid form Oxalate-NF1 of an oxalate salt of compound 1, solid form Fumarate-NF1 of a fumarate salt of compound 1, solid form Maleate-NF1 of a maleate salt of compound 1, solid form L-Malate-NF1 of a L-malate salt of compound 1.
12. The Malonate-NF1 salt of claim 10, characterized by two or more 2 θ XRPD peaks at 7.6, 15.6, and 25.0 degrees.
13. The Malonate-NF1 salt of claim 12, characterized by four or more 2 θ XRPD peaks at 7.6, 12.9, 15.6, 16.2, 20.7, 20.9, 22.4, and 25.0 degrees.
14. The Succinate-NF1 salt of claim 10, characterized by two or more 2 θ XRPD peaks at 6.7, 19.2, and 20.7 degrees.
15. The Succinate-NF1 salt of claim 14, characterized by four or more 2 θ XRPD peaks at 6.7, 14.7, 15.5, 19.2, 20.7, 21.6, and 21.9 degrees.

16. The Oxalate-NF1 salt of claim 10, characterized by two or more 2 θ XRPD peaks at 7.5, 17.8, and 19.5 degrees degrees.
17. The solid form of claim 1, characterized as a mixture of crystalline forms A1 and A2.
18. A pharmaceutical composition comprising a solid form of compound 1 of claim 1, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.
19. A solid form of compound 1 of claim 1 for use in the treatment of a BTK-mediated disorder in a patient, wherein the solid form of compound 1 of claim 1 is to be administered to said patient.
20. Use of a solid form of compound 1 of claim 1 or physiologically acceptable salts thereof, for the production of a medicament for the prophylactic or therapeutic treatment of a BTK-mediated disorder.